Levroso Long (Diphenhydramine/Melatonin)
Insomnia
ApprovedActive
Key Facts
About NovaMedica
NovaMedica operates as a specialized commercialization and local production partner for international pharmaceutical innovations in Russia. The company's strategy centers on identifying and transferring advanced medical technologies, navigating the local regulatory landscape, and ensuring local GMP manufacturing to bring products to the Russian healthcare system. Its current portfolio consists of several commercial-stage products for conditions such as dementia, migraine, pain, schizophrenia, and insomnia, indicating it is a revenue-generating entity. As a private company, it plays a role in bridging global pharmaceutical R&D with the specific needs and regulations of the Russian market.
View full company profileTherapeutic Areas
Other Insomnia Drugs
| Drug | Company | Phase |
|---|---|---|
| Cannabidiol Soft‑Gel Capsule | Avecho Biotechnology | Phase 3 |
| Nexalin Device | Nexalin Technology | Pivotal Trial |
| SILENOR | Currax Pharmaceuticals | Approved |
| CLM-IN01 | Closed Loop Medicine | Pre-commercial (UKCA/CE marked) |
| Insomnia Studies | Pacific Clinical Research Medical Group | Phase 2/3 |
| HS-10384 | Hansoh Pharma | Phase III |
| CEL-101 (C-122) | Celon Pharma | Phase II |
| CGS-2 | Canopy Growth | Phase II |